scholarly journals YAP Subcellular Localization and Hippo Pathway Transcriptome Analysis in Pediatric Hepatocellular Carcinoma

2016 ◽  
Vol 6 (1) ◽  
Author(s):  
Michael J. LaQuaglia ◽  
James L. Grijalva ◽  
Kaly A. Mueller ◽  
Antonio R. Perez-Atayde ◽  
Heung Bae Kim ◽  
...  
Author(s):  
Lei Guan ◽  
Ting Li ◽  
Nanping Ai ◽  
Wei Wang ◽  
Bing He ◽  
...  

Abstract Background MEIS2 has been identified as one of the key transcription factors in the gene regulatory network in the development and pathogenesis of human cancers. Our study aims to identify the regulatory mechanisms of MEIS2 in hepatocellular carcinoma (HCC), which could be targeted to develop new therapeutic strategies. Methods The variation of MEIS2 levels were assayed in a cohort of HCC patients. The proliferation, clone-formation, migration, and invasion abilities of HCC cells were measured to analyze the effects of MEIS2C and MEIS2D (MEIS2C/D) knockdown with small hairpin RNAs in vitro and in vivo. Chromatin immunoprecipitation (ChIP) was performed to identify MEIS2 binding site. Immunoprecipitation and immunofluorescence assays were employed to detect proteins regulated by MEIS2. Results The expression of MEIS2C/D was increased in the HCC specimens when compared with the adjacent noncancerous liver (ANL) tissues. Moreover, MEIS2C/D expression negatively correlated with the prognosis of HCC patients. On the other hand, knockdown of MEIS2C/D could inhibit proliferation and diminish migration and invasion of hepatoma cells in vitro and in vivo. Mechanistically, MESI2C activated Wnt/β-catenin pathway in cooperation with Parafibromin (CDC73), while MEIS2D suppressed Hippo pathway by promoting YAP nuclear translocation via miR-1307-3p/LATS1 axis. Notably, CDC73 could directly either interact with MEIS2C/β-catenin or MEIS2D/YAP complex, depending on its tyrosine-phosphorylation status. Conclusions Our studies indicate that MEISC/D promote HCC development via Wnt/β-catenin and Hippo/YAP signaling pathways, highlighting the complex molecular network of MEIS2C/D in HCC pathogenesis. These results suggest that MEISC/D may serve as a potential novel therapeutic target for HCC.


2020 ◽  
Vol 245 (5) ◽  
pp. 385-394 ◽  
Author(s):  
Lucía Barbier-Torres ◽  
Shelly C Lu

Prohibitin 1 is an evolutionary conserved and ubiquitously expressed protein that exerts different biological functions depending on its subcellular localization. The role of prohibitin 1 in liver cancer is controversial as it can be pro- or anti-tumorigenic. However, most of the studies to date have described prohibitin 1 primarily as a tumor suppressor in the liver. Its deficiency sensitizes the liver to cholestatic liver injury, non-alcoholic fatty liver disease, inflammatory insults, and cancer. Liver-specific Phb1-knockout mice spontaneously develop hepatocellular carcinoma, Phb1 heterozygotes are more susceptible to develop cholangiocarcinoma, and the majority of human hepatocellular carcinomas and cholangiocarcinomas have reduced prohibitin 1 expression. Consistent with a tumor suppressive role in the liver, prohibitin 1 negatively regulates proliferation in hepatocytes and human hepatocellular carcinoma and cholangiocarcinoma cell lines, and multiple oncogenic signaling pathways are activated when prohibitin 1 is deficient. Although best known as a mitochondrial chaperone, prohibitin 1 can protect the liver by mitochondrial-independent mechanisms. This review summarizes what’s known about prohibitin 1’s role in liver pathology, with the focus on hepatoprotection and carcinogenesis. Impact statement This review summarizes the last decades of research on PHB1 in liver pathobiology. PHB1 is a key player for liver health as it is hepatoprotective and tumor suppressive. We highlight the importance of PHB1’s subcellular localization, post-translational modifications, and interacting proteins as major determinants of PHB1 cytoprotective function and anti-tumor activity in the liver.


2015 ◽  
Vol 91 (5) ◽  
pp. 399-406 ◽  
Author(s):  
Xinna Wang ◽  
Jianmei Luo ◽  
Albert Wingnang Leung ◽  
Yajun Li ◽  
Hongwei Zhang ◽  
...  

2017 ◽  
Vol 400 ◽  
pp. 175-182 ◽  
Author(s):  
Xuan Shi ◽  
Hai-Rong Zhu ◽  
Tao-Tao Liu ◽  
Xi-Zhong Shen ◽  
Ji-Min Zhu

BMC Cancer ◽  
2010 ◽  
Vol 10 (1) ◽  
Author(s):  
Huaqing Cui ◽  
Feng Wu ◽  
Yanling Sun ◽  
Guocai Fan ◽  
Qingming Wang

2013 ◽  
Vol 30 (4) ◽  
Author(s):  
Lianjie Lin ◽  
Dongxu Wang ◽  
Nan Cao ◽  
Yan Lin ◽  
Yu Jin ◽  
...  

Tumor Biology ◽  
2016 ◽  
Vol 37 (10) ◽  
pp. 13323-13331 ◽  
Author(s):  
Cheng-Bo Yu ◽  
Li-Yao Zhu ◽  
Yu-Gang Wang ◽  
Fen Li ◽  
Xiao-Yu Zhang ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document